|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
2
|
DeSantis C, Siegel R, Bandi P and Jemal A:
Breast cancer statistics, 2011. CA Cancer J Clin. 61:409–418. 2011.
View Article : Google Scholar
|
|
3
|
Smith NZ: Treating metastatic breast
cancer with systemic chemotherapies: current trends and future
perspectives. Clin J Oncol Nurs. 16:E33–E43. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gonzalez-Angulo AM, Morales-Vasquez F and
Hortobagyi GN: Overview of resistance to systemic therapy in
patients with breast cancer. Adv Exp Med Biol. 608:1–22. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ramachandran S: Synthesis and
antimicrobial evaluation of some novel schiff and mannich bases of
isatin derivatives. Int J Res Pharm Chem. 1:289–294. 2011.
|
|
6
|
Medvedev A, Igosheva N, Crumeyrolle-Arias
M and Glover V: Isatin: role in stress and anxiety. Stress.
8:175–183. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pandeya SN, Smitha S, Jyoti M and Sridhar
SK: Biological activities of isatin and its derivatives. Acta
Pharm. 55:27–46. 2005.PubMed/NCBI
|
|
8
|
Medvedev A, Buneeva O and Glover V:
Biological targets for isatin and its analogues: implications for
therapy. Biologics. 1:151–162. 2007.PubMed/NCBI
|
|
9
|
Vine KL, Matesic L, Locke JM, Ranson M and
Skropeta D: Cytotoxic and anticancer activities of isatin and its
derivatives: a comprehensive review from 2000–2008. Anticancer
Agents Med Chem. 9:397–414. 2009.PubMed/NCBI
|
|
10
|
Cane A, Tournaire MC, Barritault D and
Crumeyrolle-Arias M: The endogenous oxindoles 5-hydroxyoxindole and
isatin are antiproliferative and proapoptotic. Biochem Biophys Res
Commun. 276:379–384. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sun L, Liang C, Shirazian S, Zhou Y,
Miller T, Cui J, Fukuda JY, et al: Discovery of
5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic
acid (2-diethylaminoethyl) amide, a novel tyrosine kinase inhibitor
targeting vascular endothelial and platelet-derived growth factor
receptor tyrosine kinase. J Med Chem. 46:1116–1119. 2003.
|
|
12
|
Polychronopoulos P, Magiatis P,
Skaltsounis AL, Myrianthopoulos V, Mikros E, Tarricone A, Musacchio
A, et al: Structural basis for the synthesis of indirubins as
potent and selective inhibitors of glycogen synthase kinase-3 and
cyclin-dependent kinases. J Med Chem. 47:935–946. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Krishnegowda G, Prakasha Gowda AS, Tagaram
HR, Carroll KF, Irby RB, Sharma AK and Amin S: Synthesis and
biological evaluation of a novel class of isatin analogs as dual
inhibitors of tubulin polymerization and Akt pathway. Bioorg Med
Chem. 19:6006–6014. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang C and Youle RJ: The role of
mitochondria in apoptosis. Annu Rev Genet. 43:95–118. 2009.
View Article : Google Scholar
|
|
15
|
Volkmann N, Marassi FM, Newmeyer DD and
Hanein D: The rheostat in the membrane: BCL-2 family proteins and
apoptosis. Cell Death Differ. 21:206–215. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cory S, Huang DC and Adams JM: The Bcl-2
family: roles in cell survival and oncogenesis. Oncogene.
24:8590–8607. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cottet-Rousselle C, Ronot X, Leverve X and
Mayol JF: Cytometric assessment of mitochondria using fluorescent
probes. Cytometry A. 79:405–425. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pakravan P, Kashanian S, Khodaei MM and
Harding FJ: Biochemical and pharmacological characterization of
isatin and its derivatives: from structure to activity. Pharmacol
Rep. 65:313–335. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Premanathan M, Radhakrishnan S,
Kulangiappar K, Singaravelu G, Thirumalaiarasu V, Sivakumar T and
Kathiresan K: Antioxidant & anticancer activities of isatin
(1H-indole-2,3-dione), isolated from the flowers of Couroupita
guianensis Aubl. Indian J Med Res. 136:822–826. 2012.
|
|
20
|
de Cândido-Bacani PM, Mori MP, Calvo TR,
Vilegas W, Varanda EA and Cólus IM: In vitro assessment of the
cytotoxic, apoptotic, and mutagenic potentials of isatin. J Toxicol
Environ Health A. 76:354–362. 2013.PubMed/NCBI
|
|
21
|
Ashkenazi A and Dixit VM: Death receptors:
signaling and modulation. Science. 281:1305–1308. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Reed JC: Double identity for proteins of
the Bcl-2 family. Nature. 387:773–776. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bedikian AY, Millward M, Pehamberger H,
Conry R, Gore M, Trefzer U, Pavlick AC, et al: Bcl-2 antisense
(oblimersen sodium) plus dacarbazine in patients with advanced
melanoma: the oblimersen melanoma study group. J Clin Oncol.
24:4738–4745. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Indran IR, Tufo G, Pervaiz S and Brenner
C: Recent advances in apoptosis, mitochondria and drug resistance
in cancer cells. Biochim Biophys Acta. 1807:735–745. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hengartner MO: The biochemistry of
apoptosis. Nature. 407:770–776. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kuranaga E: Caspase signaling in animal
development. Dev Growth Differ. 53:137–148. 2011. View Article : Google Scholar
|
|
27
|
Yoshida A, Pommier Y and Ueda T:
Endonuclease activation and chromosomal DNA fragmentation during
apoptosis in leukemia cells. Int J Hematol. 84:31–37. 2006.
View Article : Google Scholar : PubMed/NCBI
|
